Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

Phase 1 Terminated 1 enrolled Weill Medical College of Cornell University

NaSingle-groupOpen-labelTreatment

Summary

This study will test the safety and efficacy of intra-arterial chemotherapy in subjects with newly diagnosed, residual, or recurrent atypical choroid plexus papilloma and choroid plexus carcinoma prior to a second surgery. It is believed that intra-arterial chemotherapy will be safe and feasible for this population and will result in decreased tumor size, which may further improve the goals of a second-look surgery.

Timeline

Start: 2023-05-04
Primary completion: 2024-07-23
Completion: 2025-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 mg/ml	Other
Subject	Melphalan	Small molecule	0.5 mg/ml	Other
Subject	Topotecan	Small molecule	0.2 mg/ml	Other

Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

Summary

Timeline

Drugs

Indications